India
· Delayed Price · Currency is INR Piramal Pharma Statistics
Total Valuation
Piramal Pharma has a market cap or net worth of INR 290.39 billion. The enterprise value is 333.75 billion.
| Market Cap | 290.39B |
| Enterprise Value | 333.75B |
Important Dates
The last earnings date was Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.33B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.41% |
| Shares Change (QoQ) | +7.88% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 607.57M |
Valuation Ratios
The trailing PE ratio is 318.66 and the forward PE ratio is 59.67.
| PE Ratio | 318.66 |
| Forward PE | 59.67 |
| PS Ratio | 3.13 |
| PB Ratio | 3.57 |
| P/TBV Ratio | 7.19 |
| P/FCF Ratio | 127.41 |
| P/OCF Ratio | 32.54 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.20, with an EV/FCF ratio of 146.43.
| EV / Earnings | 366.23 |
| EV / Sales | 3.59 |
| EV / EBITDA | 20.20 |
| EV / EBIT | 39.91 |
| EV / FCF | 146.43 |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.60.
| Current Ratio | 1.54 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 3.07 |
| Debt / FCF | 21.31 |
| Interest Coverage | 1.81 |
Financial Efficiency
Return on equity (ROE) is 1.14% and return on invested capital (ROIC) is 3.73%.
| Return on Equity (ROE) | 1.14% |
| Return on Assets (ROA) | 3.08% |
| Return on Invested Capital (ROIC) | 3.73% |
| Return on Capital Employed (ROCE) | 6.41% |
| Revenue Per Employee | 13.82M |
| Profits Per Employee | 135,630 |
| Employee Count | 6,719 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 1.44 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +39.23% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +39.23% |
| 50-Day Moving Average | 213.45 |
| 200-Day Moving Average | 224.20 |
| Relative Strength Index (RSI) | 54.27 |
| Average Volume (20 Days) | 165,221 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Piramal Pharma had revenue of INR 92.86 billion and earned 911.30 million in profits. Earnings per share was 0.68.
| Revenue | 92.86B |
| Gross Profit | 60.54B |
| Operating Income | 7.63B |
| Pretax Income | 4.15B |
| Net Income | 911.30M |
| EBITDA | 15.39B |
| EBIT | 7.63B |
| Earnings Per Share (EPS) | 0.68 |
Balance Sheet
The company has 5.21 billion in cash and 48.56 billion in debt, giving a net cash position of -43.35 billion.
| Cash & Cash Equivalents | 5.21B |
| Total Debt | 48.56B |
| Net Cash | -43.35B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 81.25B |
| Book Value Per Share | 61.40 |
| Working Capital | 20.31B |
Cash Flow
In the last 12 months, operating cash flow was 8.92 billion and capital expenditures -6.64 billion, giving a free cash flow of 2.28 billion.
| Operating Cash Flow | 8.92B |
| Capital Expenditures | -6.64B |
| Free Cash Flow | 2.28B |
| FCF Per Share | n/a |
Margins
Gross margin is 65.20%, with operating and profit margins of 8.22% and 0.98%.
| Gross Margin | 65.20% |
| Operating Margin | 8.22% |
| Pretax Margin | 4.47% |
| Profit Margin | 0.98% |
| EBITDA Margin | 16.57% |
| EBIT Margin | 8.22% |
| FCF Margin | 2.45% |
Dividends & Yields
This stock pays an annual dividend of 0.11, which amounts to a dividend yield of 0.05%.
| Dividend Per Share | 0.11 |
| Dividend Yield | 0.05% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 15.88% |
| Buyback Yield | -4.41% |
| Shareholder Yield | -4.36% |
| Earnings Yield | 0.31% |
| FCF Yield | 0.78% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |